Geron Corp News - GERN

Empower your portfolio: Real-time discussions and actionable trading ideas.

Class Action Filed Against Geron Corporation (GERN) Seeking Recovery for Investors - Contact The Gross Law Firm

Class Action Filed Against Geron Corporation (GERN) Seeking Recovery for Investors - Contact The Gross Law...

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an...

Form 8-K/A - Current report: [Amend]

GERN Investors Have Opportunity to Lead the Geron Corporation Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - GERN

GERN Investors Have Opportunity to Lead the Geron Corporation Securities Lawsuit - Contact the DJS Law Group...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Achieved $47.5 million in RYTELO™ (imetelstat) net product revenue in Q4 2024 and $76.5 million since commercial launch at the end of June 2024...

Geron to Participate at Upcoming Investor Conferences in March 2025

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that members of the management team are scheduled...

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an...

Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its fourth quarter and...

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an...

Form 8-K - Current report

Form S-8 - Securities to be offered to employees in employee benefit plans

learningcurve2020 2 days ago

Grrrron. But I’m hanging in there with them. Seems like a prime candidate now for a takeover. Now we see why they dropped the price. Terrible considering the analyst calls.

>> (Nasdaq: GERN) has announced the granting of equity awards to three newly hired employees as inducement for their employment. The awards, granted on March 17, 2025, consist of:

150,000 shares in stock options with an exercise price of $1.74 per share
75,000 shares in restricted stock units (RSUs)
The stock options have a 10-year term with a vesting schedule of 12.5% after six months and the remaining shares vesting over 42 months. RSUs vest 25% annually over four years. These awards were granted under Geron's 2018 Inducement Award Plan and comply with Nasdaq Listing Rule 5635(c)(4).

Lawsuit:
>>According to the complaint, during the class period, defendants failed to disclose to investors that
Geron’s optimistic reports of Rytelo’s launch success and potential growth fell short of reality; the impacts of seasonality, existing competition, and the burden of continued monitoring played a much more significant role in patient starts than defendants had implied. Moreover, Rytelo lacked the necessary awareness to penetrate the market, resulting in an inability for Geron to capitalize on the purportedly significant unmet need for the drug, particularly among first-line patients and those outside the academic setting.

The complaint alleges that on February 26, 2025, Geron announced its financial results for the fourth quarter of fiscal 2024, disclosing that Rytelo’s growth had flattened over the preceding months. The Company attributed the diminished growth on seasonality, competition, lack of awareness for Rytelo, and the burden of the monitoring requirement necessary for the drug treatment. On this news, the price of Geron’s common stock declined from a closing price of $2.37 per share on February 25, 2025, to $1.61 per share on February 26, 2025, a decline of about 32.07% in the span of just a single day.

👍️0

big bambino 2 days ago

Nice another law suit. I received a check for $7,023.42 on the first law suit, lol. maybe I'll pick up another check 😀

👍️0

KIPK 3 days ago

LOLC2020 - Karmic Karma!!

👍️0

learningcurve2020 1 week ago

Get back in your box, Gimp.

👍️0

KIPK 1 week ago

LOLC2020? Marketer for global sales??
Put an add on X.. LOL. LOLC

👍️0

learningcurve2020 1 week ago

Possible. But Scarlett was always better at drug development. Plus he’s getting up there. What Geron needs now is a great marketer for global sales.

👍️0

attilathehunt 1 week ago

Perhaps CEO needs to get out of the way for a BO to happen.

👍️0

Stumblebum 2 weeks ago

And European approval just was announced also

👍️ 1

attilathehunt 2 weeks ago

CEO stepping down...

Good news????

learningcurve2020 3 weeks ago

Oh wow, nice! I hadn’t noticed. Always encouraging. Hopefully more to come.

👍️0

luckygm 3 weeks ago

The insiders were bullish buying shares on the open market last Thursday.

👍️0

KIPK 3 weeks ago

Its the "Too Little Tooo Late" story for GERN..
LOLC??? SMH
KARMA

👍️0

learningcurve2020 3 weeks ago

Shouldn’t be down here but it is. Analyst are all over the place. Institutional holdings look good so far unless they’re dumping. We need a more dynamic management, IMO.

“B. Riley downgrades to Neutral from Buy, Cuts target to $2 from $3.50”

👙 1

big bambino 3 weeks ago

looking for 2.25 by next week

learningcurve2020 3 weeks ago

That’s all I need too. You know their governance over on the other board is atrocious, right? Rarely leads to anything good. At least Geron’s management bench runs deep. I wish they’d be more active with open market purchases but if the company is really in takeover mode that wouldn’t be possible, of course. Three presentations coming in the next weeks. We’ll see.

👍️0

attilathehunt 3 weeks ago

Here we agree. On the other board not so much.

By the way, I only have one account on ihub.

👍️0

learningcurve2020 3 weeks ago

It would be one explanation for the action today and faux stock downgrades.

“Wedbush Lowers Geron’s Price Target to $7 from $8, Outperform Raiting Maintained”

👍️0

attilathehunt 3 weeks ago

The takedown before the buyout!!

The same happen with HGSI

👍 1 💯 1

KIPK 3 weeks ago

LOLC2020 - You pumped it, Its failing & you now saying "THE COMPANY IS SOLID", BUT the "ANALYSTS SEEM INTENT ON SETTING THE STOCK FOR FAILURE??

Who pays you for such misjudged PUMP Efforts here & FUD Efforts there???

👍️0

learningcurve2020 3 weeks ago

This would be a very good time for some open market purchases by management.

👍️0

learningcurve2020 3 weeks ago

The company seems solid but the analyst seem intent on setting up the stock for failure.

👍️0

learningcurve2020 3 weeks ago

And you think someone would believe that why?

👍️0

big bambino 3 weeks ago

Great purchase. picked up another 5k @ 1.92

👍️0

learningcurve2020 3 weeks ago

All seems good but the stock is always a death trap.

>>Selling, general and administrative expenses for the three and twelve months ended December 31, 2024, were $43.4 million, and $145.7 million, respectively, and $21.4 million and $69.1 million for the same periods in 2023. The increase in general and administrative expenses in 2024 as compared to 2023 primarily reflects higher personnel-related expenses related to increased headcount to support commercial launch of RYTELO in the U.S. and stock-based compensation expense recognized upon FDA approval of RYTELO due to the vesting of performance-based stock options.

👍️0

seward 3 weeks ago

picked up another 10000 at 1.60

👍️0

learningcurve2020 3 weeks ago

Grrron stock is just a disgrace…A perpetual retail trap.

💯 1

big bambino 4 weeks ago

picked up another 4500@ $2.40

👍️0

big bambino 4 weeks ago

pushing this thing down low with no news and no volume, amazing. Will wait till Wednesday before making decision.

👍️0

KIPK 4 weeks ago

But in your Case, LC2020, a response from GROK not needed as ihub has all of YOU!!!

🪠 1

KIPK 4 weeks ago

You have been made - Historical/Present Records Been Collected!!

KARMA!!

🪠 1

Stumblebum 4 weeks ago

Earnings next week….looking for revs in the $40-$50 mil range…..up nicely from last quarter…hopefully some sort of update on European drug approval….that should happen mid year….only way to go is up from here

👍️ 1

learningcurve2020 4 weeks ago

What are you babbling about now?

👍️0

KIPK 4 weeks ago

LC-2020,

You know Your Effort to Earn are Well Documented, RIGHT??

KARMA

👍️0

learningcurve2020 1 month ago

A coming next week.

👍️0

learningcurve2020 1 month ago

WTF! Is Geron stock just a forever retail trap or are we going to see a real run?

“B. Riley Adjusts target to $3.50 From $5.50, Maintains Buy Rating”

👍️0

KIPK 1 month ago

LOL -LC2020: And as per your folowing post..

>>> That should give them about another month to dump shares before we learn anything>>>

There has never been "WE". You paid to work against the "WE", you pretend to be part of...
KARMA!!!!

🪠 1

learningcurve2020 1 month ago

Grrrrron. So disappointing. Hopefully just a shake out before the coming q report.

👍️0

learningcurve2020 1 month ago

What do you mean, I’ve been somewhat supportive of Geron?

👍️0

learningcurve2020 1 month ago

You and the other disciples always get it wrong.

KEEP SINGING DEMOCRATS -- AND DOGE WILL KEEP CUTTING.pic.twitter.com/5lYnlI2Qlq— Citizen Free Press (@CitizenFreePres) February 12, 2025

👍️ 1

learningcurve2020 1 month ago

Hopefully market acceptance increasing. Buyout is always on the table now that they said they likely won’t do a cash raise. I’m hoping for some long-shot unexpected benefit suddenly seen in some other indication.

👍️0

Stumblebum 1 month ago

Better than expected revenues? Date when they expect European approval?…..I’m buying call options !!!!!!…..not shares

👍️0

big bambino 1 month ago

Someone knows something? High volume the last week, with a sizeable uptick.

👍️0

learningcurve2020 1 month ago

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2024 financial results and business highlights before the market opens on Wednesday, February 26, 2025 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.m. Eastern Time the same day.

👍️0

KIPK 2 months ago

You are a Karmic Poison to You!!

👍️0

learningcurve2020 2 months ago

https://s201.q4cdn.com/710325604/files/doc_presentations/2025/Jan/13/JPM-2025-Corporate-Slides_final-2.pdf

👍️0

learningcurve2020 2 months ago

Who knows?? IBB is going sideways, New POTUS, nervous market. Perhaps a buyout is coming?? Perhaps something we’re not being told?? You never know in the biotech space. But all I can say is Geron has never looked better in the decades I’ve been around.

👍️0

attilathehunt 2 months ago

why the stock is doing so poorly

The MMs are on the hook for too many options in the money above $3....Wait for move next week.

👍️0

Spike5 2 months ago

Ok fair enough but tell me why the stock is doing so poorly

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Geron Corp (GERN)

Empower your portfolio: Real-time discussions and actionable trading ideas.

GERN News

Class Action Filed Against Geron Corporation (GERN) Seeking Recovery for Investors - Contact The Gross Law Firm

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form 8-K/A - Current report: [Amend]

GERN Investors Have Opportunity to Lead the Geron Corporation Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - GERN

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Geron to Participate at Upcoming Investor Conferences in March 2025

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form 8-K - Current report

Form S-8 - Securities to be offered to employees in employee benefit plans

GERN Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Geron Corp (GERN) News

Geron Corp (GERN)

Empower your portfolio: Real-time discussions and actionable trading ideas.

GERN News

Class Action Filed Against Geron Corporation (GERN) Seeking Recovery for Investors - Contact The Gross Law Firm

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form 8-K/A - Current report: [Amend]

GERN Investors Have Opportunity to Lead the Geron Corporation Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - GERN

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Geron to Participate at Upcoming Investor Conferences in March 2025

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form 8-K - Current report

Form S-8 - Securities to be offered to employees in employee benefit plans

GERN Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free